Q: What is Elevidys used for?

Elevidys is used to treat Duchenne muscular dystrophy .

Q: How does Elevidys work?

Mechanism of Action Duchenne muscular dystrophy (DMD) is caused by a genetic mutation that prevents the body from making dystrophin. Dystrophin is a vital protein that acts like a shock absorber for muscle fibers, protecting them from injury when muscles contract and relax. Without enough dystrophin, muscle cells become fragile and break down over time. Elevidys works by addressing the underlying genetic cause of the disease. It is a one-time gene therapy that uses a viral vector to deliver a specially designed gene into the patient's muscle tissue. This process involves several steps: Delivery: A modified, non-harmful virus (adeno-associated virus) carries a functional gene into the muscle cells. Protein Production: Once the gene is inside the cells, it provides instructions for the body to produce a shortened version of the dystrophin protein, known as Elevidys micro-dystrophin. Muscle Protection: This micro-dystrophin protein is designed to perform some of the essential functions of the missing natural protein, helping to stabilize and protect muscle fibers from breaking down. While the micro-dystrophin produced by Elevidys is smaller than the protein found in people without DMD, it contains the critical components needed to support muscle cell integrity.

Q: What are the active ingredients in Elevidys?

The active ingredient in Elevidys is delandistrogene moxeparvovec .

Q: What are the side effects of Elevidys?

Common side effects of Elevidys may include: vomiting nausea fever and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Elevidys?

Elevidys belongs to the gene therapy drug class.

Q: What is the dosage of Elevidys and how do I take it?

Administration Elevidys is given as a single dose through an intravenous (IV) infusion into a vein. The procedure is performed by a healthcare provider in a clinical setting, such as a hospital or specialized infusion center. The infusion typically takes one to two hours to complete. Before and After Treatment To prepare for the infusion and reduce the risk of certain side effects, a healthcare provider will prescribe a course of corticosteroid medication. This usually begins the day before the infusion and continues for several weeks afterward. It is important to follow the specific schedule provided by the doctor for these medications. Healthcare providers will also perform several blood tests before the treatment to confirm eligibility. Following the infusion, regular blood tests are required for several months to monitor liver function, platelet counts, and heart health markers.

Q: Is Elevidys safe during pregnancy and breastfeeding?

Pregnancy Elevidys is indicated for the treatment of Duchenne muscular dystrophy, a genetic condition that primarily affects males. Because of this, the medication is not intended for use in women. There are no clinical studies or data regarding the use of Elevidys in pregnant individuals. It is unknown if the medication could cause harm to a developing fetus. Additionally, animal reproduction studies have not been conducted to evaluate the potential risks of this gene therapy during pregnancy. Breastfeeding There is no information available concerning the presence of Elevidys in human breast milk. It is also unknown how the medication might affect a breastfed infant or the production of milk. Individuals with questions about gene therapy and its potential impacts should consult their healthcare provider.

Q: What forms and strengths does Elevidys come in?

Dosage Forms Elevidys is a sterile, preservative-free suspension intended for intravenous infusion. It is supplied in a kit containing multiple vials. Packaging The medication is provided in kits tailored to the patient's weight. Each kit contains the required number of vials for the treatment.

Q: What is the FDA approval status of Elevidys?

FDA Approval History Elevidys (delandistrogene moxeparvovec-rokl) first received accelerated approval from the U.S. Food and Drug Administration (FDA) in June 2023. This initial approval was limited to ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) and a confirmed mutation in the DMD gene. In June 2024, the FDA expanded the approval to include a broader population. The current regulatory status includes: Traditional Approval: Granted for the treatment of ambulatory patients aged 4 years and older with DMD and a confirmed mutation in the DMD gene. Accelerated Approval: Granted for the treatment of non-ambulatory patients aged 4 years and older with DMD and a confirmed mutation in the DMD gene. Continued approval for this specific group may be contingent upon verification of clinical benefit in confirmatory trials. Regulatory Considerations The FDA has identified certain limitations and safety considerations for the use of Elevidys: Contraindications: The therapy is not approved for patients with any deletion in exon 8 and/or exon 9 of the DMD gene due to safety risks. Post-Marketing Requirements: As part of the accelerated approval process, the manufacturer is required to conduct further clinical studies to confirm the drug's clinical benefit in non-ambulatory patients. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for this medication.

Question 1

What is Elevidys?

Accepted Answer

Elevidys is a gene therapy that delivers a functional gene into muscle cells to produce a shortened version of the dystrophin protein. It uses a viral vector to transport genetic instructions that enable the production of micro-dystrophin, which is necessary for the structural stability of muscle tissue.

The therapy is designed to address genetic mutations that prevent the body from producing sufficient natural dystrophin. By introducing these genetic instructions, the treatment aims to support muscle health at a cellular level.

Question 2

What is Elevidys used for?

Accepted Answer

Elevidys is used to treat Duchenne muscular dystrophy.

Question 3

How does Elevidys work?

Accepted Answer

Mechanism of Action

Duchenne muscular dystrophy (DMD) is caused by a genetic mutation that prevents the body from making dystrophin. Dystrophin is a vital protein that acts like a shock absorber for muscle fibers, protecting them from injury when muscles contract and relax. Without enough dystrophin, muscle cells become fragile and break down over time.

Elevidys works by addressing the underlying genetic cause of the disease. It is a one-time gene therapy that uses a viral vector to deliver a specially designed gene into the patient's muscle tissue. This process involves several steps:

Delivery: A modified, non-harmful virus (adeno-associated virus) carries a functional gene into the muscle cells.
Protein Production: Once the gene is inside the cells, it provides instructions for the body to produce a shortened version of the dystrophin protein, known as Elevidys micro-dystrophin.
Muscle Protection: This micro-dystrophin protein is designed to perform some of the essential functions of the missing natural protein, helping to stabilize and protect muscle fibers from breaking down.

While the micro-dystrophin produced by Elevidys is smaller than the protein found in people without DMD, it contains the critical components needed to support muscle cell integrity.

Question 4

What are the active ingredients in Elevidys?

Accepted Answer

The active ingredient in Elevidys is delandistrogene moxeparvovec.

Question 5

What are the side effects of Elevidys?

Accepted Answer

Common side effects of Elevidys may include:

vomiting
nausea
fever
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Elevidys?

Accepted Answer

Elevidys belongs to the gene therapy drug class.

Question 7

What is the dosage of Elevidys and how do I take it?

Accepted Answer

Administration

Elevidys is given as a single dose through an intravenous (IV) infusion into a vein. The procedure is performed by a healthcare provider in a clinical setting, such as a hospital or specialized infusion center. The infusion typically takes one to two hours to complete.

Before and After Treatment

To prepare for the infusion and reduce the risk of certain side effects, a healthcare provider will prescribe a course of corticosteroid medication. This usually begins the day before the infusion and continues for several weeks afterward. It is important to follow the specific schedule provided by the doctor for these medications.

Healthcare providers will also perform several blood tests before the treatment to confirm eligibility. Following the infusion, regular blood tests are required for several months to monitor liver function, platelet counts, and heart health markers.

Question 8

Is Elevidys safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Elevidys is indicated for the treatment of Duchenne muscular dystrophy, a genetic condition that primarily affects males. Because of this, the medication is not intended for use in women.

There are no clinical studies or data regarding the use of Elevidys in pregnant individuals. It is unknown if the medication could cause harm to a developing fetus. Additionally, animal reproduction studies have not been conducted to evaluate the potential risks of this gene therapy during pregnancy.

Breastfeeding

There is no information available concerning the presence of Elevidys in human breast milk. It is also unknown how the medication might affect a breastfed infant or the production of milk. Individuals with questions about gene therapy and its potential impacts should consult their healthcare provider.

Question 9

What forms and strengths does Elevidys come in?

Accepted Answer

Dosage Forms

Elevidys is a sterile, preservative-free suspension intended for intravenous infusion. It is supplied in a kit containing multiple vials.

Packaging

The medication is provided in kits tailored to the patient's weight. Each kit contains the required number of vials for the treatment.

Question 10

What is the FDA approval status of Elevidys?

Accepted Answer

FDA Approval History

Elevidys (delandistrogene moxeparvovec-rokl) first received accelerated approval from the U.S. Food and Drug Administration (FDA) in June 2023. This initial approval was limited to ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) and a confirmed mutation in the DMD gene.

In June 2024, the FDA expanded the approval to include a broader population. The current regulatory status includes:

Traditional Approval: Granted for the treatment of ambulatory patients aged 4 years and older with DMD and a confirmed mutation in the DMD gene.
Accelerated Approval: Granted for the treatment of non-ambulatory patients aged 4 years and older with DMD and a confirmed mutation in the DMD gene. Continued approval for this specific group may be contingent upon verification of clinical benefit in confirmatory trials.

Regulatory Considerations

The FDA has identified certain limitations and safety considerations for the use of Elevidys:

Contraindications: The therapy is not approved for patients with any deletion in exon 8 and/or exon 9 of the DMD gene due to safety risks.
Post-Marketing Requirements: As part of the accelerated approval process, the manufacturer is required to conduct further clinical studies to confirm the drug's clinical benefit in non-ambulatory patients.

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for this medication.

Question 11

What should I know about Elevidys and cost?

Accepted Answer

Cost Considerations

Elevidys is a specialized gene therapy administered as a single intravenous infusion. Because it is a one-time treatment rather than a recurring medication, the cost structure differs from traditional drugs taken daily or monthly.

Insurance and Out-of-Pocket Costs

The amount a patient pays for Elevidys will vary based on their specific health insurance plan. Factors that influence the final cost include:

Insurance provider and specific plan benefits.
Deductibles and out-of-pocket maximums.
Prior authorization requirements from the insurance company.

Financial Assistance

Support programs may be available to help families manage the costs associated with this treatment. These programs often provide assistance with navigating insurance claims or offer financial aid to those who qualify based on medical and financial criteria.

Additional Expenses

Beyond the cost of the drug itself, patients may incur expenses related to the administration process, including:

Specialized medical facility fees for the infusion.
Required laboratory tests and monitoring before and after the procedure.
Travel and lodging if the treatment is performed at a specialized center far from home.

Elevidys

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Elevidys

Hospitals.net Disclosure